retatrutide triple hormone receptor agonist mechanism of action – What is Reta? – People who've seen the news about Phase 3 trial results wanting to learn more (informational) RETATRUTIDE: A Medication for Diabetes

SGLT2 inhibition with empagliflozin as a possible therapeutic option for postprandial hypoglycemia after bariatric surgery

Adjusted True Value Scores based on updated scoring data

Both medications are injected once per week on the same day of the week and can be taken with or without food

At three, six, nine and 12 months following semaglutide initiation, women using hormone therapy experienced approximately 30% greater total body weight loss than the non-hormone therapy users

References: EMC SmPC Ozempic (semaglutide)

Participants randomized to the 4 mg dose with a 2 mg starting dose had significantly fewer GI adverse events than those started directly at 4 mg